ArticleCancer science2022
Trends in cervical cancer incidence and mortality of young and middle adults in Japan.
Article in Cancer science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of camrelizumab for the treatment of cervical cancer: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- Real-world efficacy and safety of cemiplimab in Japanese patients with recurrent or metastatic cervical cancer: A single-center retrospective cohort study.Gynecologic oncology reports · 2026Article
- Survey to Document the Adverse Reactions After Human Papillomavirus Vaccination Among Japanese Female Youth at a University.The journal of obstetrics and gynaecology research · 2026Article
- Towards Global HPV Eradication: Single-Dose HPV Vaccination vs. Pseudoscience.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Article
- The effects of human papillomavirus vaccination in Japan.Human vaccines & immunotherapeutics · 2025Article
- Risk Factors of High-Grade CIN or Cervix Cancer in Young Women with Abnormal Pap Smear Results: Who Should Be Treated with LEEP (Loop Electrosurgical Excision Procedure)?Journal of clinical medicine · 2025Article
- Circular RNAs in gynecological cancer: From molecular mechanisms to clinical applications (Review).Oncology letters · 2025Review
- Overcoming HPV Vaccine Hesitancy in Japan: A Narrative Review of Safety Evidence, Risk Communication, and Policy Approaches.Vaccines · 2025Review
- Cost-effectiveness analysis of 9-valent human papillomavirus vaccine combined with screening for cervical cancer in Japan.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025Article
- Article
- Article
- Construction and validation of prognostic models for young cervical cancer patients: age stratification based on restricted cubic splines.Scientific reports · 2024Article
- Human Papillomavirus Self-Sampling for Unscreened Women Aged 24 Years During the COVID-19 Pandemic.Healthcare (Basel, Switzerland) · 2024Article
- Observational
- Estimation of self-funded human papillomavirus vaccine recipients from Japan's previously assumed "unvaccinated generation".Cancer science · 2024Article
- Even though active recommendation for HPV vaccination has restarted, Japan's rates have not recovered.Cancer science · 2024Article
- Effectiveness of catch-up and routine program of the 9-valent vaccine on cervical cancer risk reduction in Japan.Cancer science · 2024Article
- Transcriptomic era of cancers in females: new epigenetic perspectives and therapeutic prospects.Frontiers in oncology · 2024Review
- Dual roles of cellular communication network factor 6 (CCN6) in the invasion and metastasis of oral cancer cells to bone via binding to BMP2 and RANKL.Carcinogenesis · 2023Article
- Cancer Prevalence Projections in Japan and Decomposition Analysis of Changes in Cancer Burden, 2020-2050: A Statistical Modeling Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In most high-resource countries with organized screening programs, the incidence and mortality of cervical cancer is decreasing. Recent statistics have also revealed a reduction in invasive cervical cancer incidence as a result of national vaccination programs. Paradoxically, cervical cancer incidence has increased in Japan, particularly amongst women of reproductive age. This study aimed to examine the trends in cervical cancer incidence and mortality for young and middle adult women in Japan, by analyzing trends in 10-year interval age-groups. Cervical cancer incidence for young and middle adult women (ages 20-59 years) was obtained from high-quality population-based cancer registries in three prefectures from 1985 to 2015. National cancer mortality data were obtained from published vital statistics from 1985 to 2019. Trends in crude and age-standardized rates (ASR) were analyzed using Joinpoint regression. The cervical cancer incidence trend in 20-59-year-old women combined significantly increased over the observation period. Both crude and ASR increased from 1985 to 2015 with an annual percent change (APC) of +1.6% (95% confidence interval, 1.1, 2.1) and +1.7% (1.2, 2.3), respectively. Similar increases were seen in ages 20-29, 30-39, and 40-49 years with higher APCs especially in 20s and 30s. Both crude and ASR mortality significantly increased after the early 1990s in ages 20-59 years combined. Based on the recognition that current cervical cancer control strategies in Japan have not been effective in reducing the cervical cancer burden in young and middle adults, promotion of screening and vaccination should be urgently strengthened.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.